Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/08/22
End: 01/02/24
Due: 01/02/25
Phase: N/A
Priority: Normal
Start: 12/26/22
End: 03/27/23
Due: 03/27/24
Phase: N/A
Priority: Normal
Start: 03/21/24
End: 05/25/24
Due: 05/25/25
Phase: N/A
Priority: Normal
Start: 09/11/24
End: 08/31/26
Due: 08/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors | NCT06873542 | Heronova Pharmaceuticals | user2@example.com | None | 2022-07-08 | 2024-01-02 | 2025-01-02 | - | - | 2025-07-14 |
| A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects | NCT06860282 | Heronova Pharmaceuticals | user2@example.com | None | 2022-12-26 | 2023-03-27 | 2024-03-27 | - | - | 2025-07-14 |
| Relative Bioavailability Study of CX2101A for the Treatment of COVID-19 | NCT06864182 | Heronova Pharmaceuticals | user2@example.com | None | 2024-03-21 | 2024-05-25 | 2025-05-25 | - | - | 2025-07-14 |
| A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | NCT06873555 | Heronova Pharmaceuticals | user2@example.com | None | 2024-09-11 | 2026-08-31 | 2027-08-31 | - | - | 2025-07-14 |